Novobiocin in Combination with High-Dose Chemotherapy for the Treatment of Advanced Breast Cancer: A Phase 2 Study

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 3 A, 2000, Pages 335-343

  Hahm, Hillary A ^a,c   Armstrong, Deborah K ^a   Chen, Ting Ling ^a,d   Grochow, Louise ^a,e   Passos Coelho, Jose ^a,f   Goodman, Steven N ^a   Davidson, Nancy E ^a   Kennedy, M John ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ST JAMES S HOSPITAL   (Ireland)

^c Northwest Georgia Oncology Centers   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NATIONAL CANCER INSTITUTE   (United States)

^f INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

Alkylating agents; Dose intensity; Drug resistance

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 4-HYDROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; NOVOBIOCIN; THIOTEPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CELL CULTURE; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MIDDLE AGED; NOVOBIOCIN; SURVIVAL ANALYSIS; THIOTEPA; TREATMENT FAILURE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033643238     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70059-0     Document Type: Article

References (47)

1. Peters WP, Shpall EJ, Jones R, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
2. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol. 1989;7:1824-1830.
3. Kennedy MJ, Beveridge RA, Rowley S, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991;83:920-926.
4. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992; 10:102-110.
5. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol. 1992;10:1743-1747.
6. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
7. Kennedy MJ, Armstrong DK, Huelskamp AM, et al. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol. 1995;13:1136-1143.
8. Kennedy MJ, Vogelsang GB, Jones RJ, et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing a autologous bone marrow transplantation for breast cancer. J Clin Oncol. 1994;12:249-257.
9. Dunphy FR, Spitzer G, Buzdar AU, et al. Treatment of estrogen-receptor negative or hormone refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol. 1990;8:1207-1216.
10. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
11. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162-1170.
12. Teicher BA, Cucchi CA, Lee JB. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res. 1986;46:4379-4383.
13. Frei E III, Canellos GP. Dose, a critical factor in cancer chemotherapy. Am J Med. 1980;69:585-594.
14. Mattern MR, Scudiero DA. Characterization of the inhibition of replicative and repair type DNA synthesis by novobiocin and nalidixic acid. Biochim Biophys Acta. 1981;653:248-258.
15. Eder JP, Teicher B.A, Holden SA, Cathcart KN, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest. 1987; 79:1524-1528.
16. Tan KB, Mattern M.R, Boyce RA, Schein PS. Unique sensitivity of nitrogen mustard-resistant human Burkitt lymphoma cells to novobiocin. Biochem Pharmacol. 1988;37:4411-4413.
17. Lee FY, Flannery DJ, Siemann DW. Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II. Cancer Res. 1992;52:3515-3520.
18. Dejong S, Timmer-Bosscha H, DeVries E, Mulder NH. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. Int J Cancer. 1993;53:110-117.
19. Rappa G, Lorico A, Sartorelli AC. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Int J Cancer. 1992;51:780-787.
20. Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991;51:510-513.
21. Ellis GK, Crowley J, Livingston RB, Goodwin JW, Hutchins L, Allen A. Cisplatin and novobiocin in the treatment of non-small cell lung cancer. Cancer. 1991;67:2969-2973.
22. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
23. Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex-vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med. 1986;315:141-147.
24. Passos-Coelho JL, Braine HG, Wright SK, et al. Large-volume leukapheresis using regional citrate anticoagulation to collect peripheral blood progenitor cells. J Hematother. 1995;4:11-19.
25. Passos-Coelho JL, Machado MA, Lucio P, Leal-Da-Costa F, Silva MR, Oarreira A. Large-volume leukaphereses may be more efficient than standard-volume leukaphereses for collection of peripheral blood progenitor cells. J Hematother. 1997;6:465-474.
26. Chen T-L, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res. 1995; 55:810-816.
27. Chen T-L, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos. 1997;25:544-551.
28. Cohen BE, Egorin MJ, Nayar MS, Gutierrez PL. Effects of pH and temperature on the stability and decomposition of N,N′,N″-triethylenethiophosphoramide in urine and buffer. Cancer Res. 1984;44:4312-4316.
29. Egorin MJ, Cohen BE, Kohlhepp EA, Gutierrez PL. Gas-liquid chromatographic analysis of N,N′,N″-triethylene thiophosphoramide and N,N′,N″-triethylene phosphoramide in biological samples. J Chromatogr. 1985;343:196-202.
30. O'Dwyer PJ, LaCreta F, Engstrom PF, et al. Phase I/pharmacokinetic reevaluation of thiotepa. Cancer Res. 1991;51:3171-3176.
31. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm. 1978;6:539-546.
32. Anderson LW, Chen T-L, Colvin OM, et al. Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res. 1996;2:1481-1487.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
34. Bull JM, Tormey DC, Li SH, et al. Randomized comparative trial of adriamycin vs methotrexate in combination drug therapy. Cancer. 1978;41:1649-1657.
35. Bonadonna G, Valagussa P. Chemotherapy of breast cancer: current views and results. Int J Radiat Oncol Biol Phys. 1983;9:279-297.
36. Mick R, Begg CB, Antman KH, Korzun AH, Frei E 3d. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat. 1989;13:33-38.
37. Clark G, Sledge GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5:55-61.
38. Smith GA, Henderson IC. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. Important Adv Oncol. 1995:201-214.
39. Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997;15:3171-3177.
40. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Phase in randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the 'Philadelphia' Intergroup Study (PBT-1). Proc Am Soc Clin Oncol. 1999;18:1a.
41. Colvin M, Chabner BA. Alkylating Agents. In: Chabner BA and Collins JM, eds. Cancer Chemotherapy. Philadelphia: JB Lippincott; 1990:276-313.
42. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin. 1991;20:194-208.
43. Busse E, Busch FW, Bohnenstengel F, et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol. 1997;15:1885-1896.
44. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol. 1996;14:1484-1494.
45. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol. 1992;10:995-1000.
46. Davidson NE, Kennedy MJ, and Armstrong DA. Dose-intensive chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2000:633-644.
47. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999;17:3374-3388.